-+ 0.00%
-+ 0.00%
-+ 0.00%
Onco-Innovations initiates ADME studies for lead cancer drug candidate ONC010
Share
Listen to the news
Onco-Innovations initiates ADME studies for lead cancer drug candidate ONC010
  • Onco-Innovations initiated ADME studies for ONC010, its lead nanoparticle-formulated PNKP inhibitor, to support IND-enabling development.
  • Work targets metabolism of the active pharmaceutical ingredient to inform manufacturing decisions, formulation optimization, toxicology planning.
  • Program aims to build pharmacokinetic and metabolic data to support dose selection, safety assessment, future clinical evaluation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202607161800TNWSWRCACNPR_____1knDF1lX4) on July 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending